ArticleCancers2022

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.

Walid Shalata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.